[go: up one dir, main page]

CN1288755A - Pure beta ray corrying safe microball and its preparation - Google Patents

Pure beta ray corrying safe microball and its preparation Download PDF

Info

Publication number
CN1288755A
CN1288755A CN 00125741 CN00125741A CN1288755A CN 1288755 A CN1288755 A CN 1288755A CN 00125741 CN00125741 CN 00125741 CN 00125741 A CN00125741 A CN 00125741A CN 1288755 A CN1288755 A CN 1288755A
Authority
CN
China
Prior art keywords
safe
beta ray
microball
pure beta
corrying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 00125741
Other languages
Chinese (zh)
Other versions
CN1141146C (en
Inventor
黄文旵
钱达兴
周萘
吴知方
茅波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tongji University
Original Assignee
Tongji University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tongji University filed Critical Tongji University
Priority to CNB001257412A priority Critical patent/CN1141146C/en
Publication of CN1288755A publication Critical patent/CN1288755A/en
Application granted granted Critical
Publication of CN1141146C publication Critical patent/CN1141146C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)

Abstract

载有纯β射线的安全微球及其制备方法,涉及一种载有经活化能产生治癌用的纯β射线的玻璃微球及工艺。由载有纯β射线的玻璃微球、及其采用溶胶凝胶方法涂覆在其外表面上的耐蚀涂层复合而成。本发明的最大优点是放射性同位素不易沥析游移到血液中,经体外生理模拟液浸泡试验,其相应核素的溶出率比无耐蚀涂层微球的核素的溶出率降低1~2个数量级,也无放射性污染,化学稳定性高,制备本发明的工艺简单,操作安全可靠。可广泛用于内放疗治癌。

Figure 00125741

The safety microsphere loaded with pure beta ray and its preparation method relate to a glass microsphere loaded with pure beta ray for curing cancer by activation energy and its technology. It is composed of glass microspheres loaded with pure β-rays and a corrosion-resistant coating coated on its outer surface by a sol-gel method. The greatest advantage of the present invention is that the radioactive isotope is not easy to leach and migrate into the blood, and the dissolution rate of the corresponding nuclide is 1-2 times lower than that of the nuclide without the anti-corrosion coating microsphere through the immersion test of the in vitro physiological simulation solution. order of magnitude, no radioactive pollution, high chemical stability, simple preparation process and safe and reliable operation. It can be widely used in internal radiation therapy to treat cancer.

Figure 00125741

Description

载有纯β射线的安全微球及其制备方法Safe microspheres loaded with pure beta rays and preparation method thereof

本发明涉及一种化学稳定性高的载有经活化能产生治癌用的纯β射线的玻璃微球及其工艺。The invention relates to a glass microsphere with high chemical stability loaded with pure beta ray for cancer treatment through activation energy and its technology.

开刀、化疗和放疗为传统的治癌方法。众所周知,放疗因其针对性和灵活性比化疗更大,癌症患者更愿意用放疗来直接治疗,使肿瘤缩小获得开刀机会,或使肿瘤细胞完全杀尽坏死。尽管癌细胞比正常细胞更容易吸收射线,但是,正常细胞毕竟还是受到射线的伤害。所以体外放疗的射线剂量一般都不大,不足以杀伤所有癌细胞,因此也影响了疗效。八十年代初,国外开始了介入性内放射疗法,将能放出射线的同位素与高分子树脂络合在一起,然后将其介入到体内肿瘤部位。但实际使用时发现,放射性核素与高分子结合得不牢,易脱落成离子状态,流向全身各部位,造成了更大的危害。Surgery, chemotherapy and radiotherapy are traditional cancer treatment methods. As we all know, radiotherapy is more targeted and flexible than chemotherapy. Cancer patients are more willing to use radiotherapy for direct treatment, so that the tumor can be shrunk to obtain a chance of surgery, or the tumor cells can be completely killed and necrotic. Although cancer cells absorb radiation more easily than normal cells, normal cells are still damaged by radiation after all. Therefore, the radiation dose of external radiotherapy is generally not large enough to kill all cancer cells, thus affecting the curative effect. In the early 1980s, interventional internal radiation therapy was started abroad, in which isotopes capable of emitting radiation were complexed with polymer resins, and then inserted into the tumor site in the body. However, in actual use, it was found that the combination of radionuclides and macromolecules is not strong, and it is easy to fall off into an ion state, which flows to various parts of the body, causing greater harm.

日本专利特开平5-208918公开了一种用离子溅射的方法将放射性同位素磷渗入SiO2玻璃微球外表面层,组成了放射性治疗癌症用的渗磷的玻璃微球。该发明的玻璃微球的表面层的磷容易溶解在血液中,流向全身各部位,造成危害。Japanese Patent Laid-Open No. 5-208918 discloses a method for ion sputtering to infiltrate radioactive isotope phosphorus into SiO 2 glass microsphere outer surface layer to form phosphorus-infiltrated glass microspheres for radiotherapy cancer. The phosphorus in the surface layer of the glass microspheres of the invention is easily dissolved in the blood, and flows to various parts of the whole body, causing harm.

为此,1994年1月5日我国的发明专利CN 1080266 A公开了一种磷32系列玻璃微球。它是用磷酸盐、硅酸镁、硅酸铝等盐类熔炼而成。在1991年美国专利US 5011677公开了高温熔炼成的钇铝硅玻璃微球。上述两个专利的放射性同位素虽然与玻璃体结合得比较牢,但是,共同的缺点是:仍然存在着部分放射性核素自玻璃微球沥析出来的现象,溶解在血液中,带来了对病人健康的危害。For this reason, the invention patent CN 1080266 A of my country on January 5, 1994 discloses a kind of phosphorus 32 series glass microspheres. It is smelted from salts such as phosphate, magnesium silicate, and aluminum silicate. In 1991, U.S. Patent No. 5,011,677 disclosed yttrium-aluminum-silicate glass microspheres formed by high-temperature melting. Although the radioisotopes of the above two patents are relatively firmly combined with the vitreous body, the common disadvantage is that there are still some radioactive nuclides leaching out from the glass microspheres, which dissolve in the blood and bring harm to the patient's health. harm.

本发明的目的在于设计一种放射性核素不易脱落的结构简单、使用安全、经活化成为只载有纯β射线的玻璃微球。本发明的另一个目的是提供一种制造该安全微球的方法The object of the present invention is to design a glass microsphere with simple structure, safe use and activated radionuclide that only carries pure beta rays. Another object of the present invention is to provide a method for manufacturing the safe microspheres

为了实现上述目的,本发明是这样进行的,它是由经活化能载有纯β射线的玻璃微球,及其涂覆在它的外表面上的耐蚀涂层复合而成。耐蚀涂层可以是SiO2、或/和Al2O3、或/和TiO2、或/和ZrO2。载有纯β射线的玻璃微球可以是含Y2O3、SiO2、Al2O3的Y-89玻璃微球,也可以是含P2O5、Al2O3、MgO的P-31玻璃微球。In order to achieve the above object, the present invention is carried out in that it is composed of glass microspheres loaded with pure β-rays through activation energy, and a corrosion-resistant coating coated on its outer surface. The anti-corrosion coating can be SiO 2 , or/and Al 2 O 3 , or/and TiO 2 , or/and ZrO 2 . The glass microspheres loaded with pure β rays can be Y - 89 glass microspheres containing Y 2 O 3 , SiO 2 , Al 2 O 3 , or P- 31 glass microspheres.

制备本发明的微球的步骤是;首先在玻璃微球中加入表面活性剂搅拌,表面活性剂可采用聚乙二醇或硅烷偶联剂,加入的量为每100克玻璃微球中加0.3~0.5克表面活性剂。然后将上述玻璃微球浸泡在能形成耐蚀涂层的由含正硅酸乙酯50-100%、硝酸铝0-30%、钛酸丁酯0-20%、硝酸锆0-30%组成的溶胶溶液中搅拌,使经上述处理过的玻璃微球凝胶化,接着固液分离后经旋风干燥去除有机溶剂,再在室温下陈化20-30天,最后在马弗炉内300-600℃下加热蒸发热处理,使其玻璃化,即制得本发明的表面涂覆耐蚀涂层的安全微球。本发明的玻璃微球经中子激活能载有纯β射线的核素Y-90或P-32,具有对人体所有的癌细胞都产生很强的杀死杀伤能力。The step of preparing microspheres of the present invention is; first add surfactant and stir in glass microspheres, surfactant can adopt polyethylene glycol or silane coupling agent, the amount of adding is to add 0.3 in every 100 grams of glass microspheres -0.5 g of surfactant. Then soak the above-mentioned glass microspheres in an anti-corrosion coating material containing 50-100% ethyl orthosilicate, 0-30% aluminum nitrate, 0-20% butyl titanate, and 0-30% zirconium nitrate. Stir in the sol solution to make the above-mentioned treated glass microspheres gel, then remove the organic solvent by cyclone drying after solid-liquid separation, then age at room temperature for 20-30 days, and finally in the muffle furnace for 300- Heating, evaporating and heat treatment at 600°C to make it vitrified, the safety microspheres coated with anti-corrosion coating on the surface of the present invention are obtained. The glass microsphere of the present invention can carry nuclide Y-90 or P-32 of pure beta ray through neutron activation, and has a strong ability to kill all cancer cells in the human body.

本发明的安全微球的最大的优点是安全可靠,由于在含放射性同位素玻璃微球外表牢固地涂覆了一层耐蚀涂层薄膜,使其具有极其稳定的化学性质,所以放射性同位素不易通过沥析过程游移到血液中,对周围也无放射性污染,具有非常可靠的安全性。The biggest advantage of the safe microsphere of the present invention is that it is safe and reliable. Because the outer surface of the glass microsphere containing radioisotope is firmly coated with a layer of corrosion-resistant coating film, it has extremely stable chemical properties, so radioisotope is not easy to pass through. The leaching process migrates into the blood, and there is no radioactive pollution to the surroundings, which is very reliable and safe.

本发明的安全微球还有一个优点是:在中子照射下,能被激活成含有单一的纯β射线的核素Y-90或P-32,它们能顺利地介入到体内指定部位,经动物实验和医院临床使用,证实了此类微球对人体所有的癌细胞都具有很强的杀死杀伤能力,特别是对肝癌、结肠癌、胰腺癌等格外有效。Another advantage of the safety microspheres of the present invention is that under neutron irradiation, they can be activated into nuclide Y-90 or P-32 containing a single pure beta ray, and they can be smoothly inserted into designated parts of the body. Animal experiments and clinical use in hospitals have confirmed that such microspheres have a strong ability to kill all cancer cells in the human body, especially effective against liver cancer, colon cancer, and pancreatic cancer.

本发明还有一个优点是制备方法简单易控制,用本发明的方法制得的安全微球的耐蚀涂层能牢固地粘附于玻璃微球之表面,涂层不会脱落。耐蚀涂层的组成在中子射线的激活下,不会放射出其他任何长寿命的有害杂质射线。玻璃微球与耐蚀涂层不会发生化学反应而改变各自的特性。放射性核素的溶出率比没有涂覆耐蚀涂层的原玻璃微球的溶出率降低了1~2个数量级。Another advantage of the present invention is that the preparation method is simple and easy to control, and the corrosion-resistant coating of the safety microspheres prepared by the method of the present invention can firmly adhere to the surface of the glass microspheres, and the coating will not fall off. The composition of the corrosion-resistant coating will not emit any other long-lived harmful impurity rays under the activation of neutron rays. The glass microspheres and the corrosion-resistant coating will not chemically react to change their respective characteristics. The dissolution rate of the radionuclides is 1-2 orders of magnitude lower than that of the original glass microspheres without the anti-corrosion coating.

本发明的具体结构和制造方法由以下的实施例及其附图给出。The specific structure and manufacturing method of the present invention are given by the following examples and accompanying drawings.

图1为本发明的结构示意图。Fig. 1 is a structural schematic diagram of the present invention.

图2为本发明的工艺流程图。Fig. 2 is a process flow diagram of the present invention.

下面结合附图对本发明作进一步的描述;Below in conjunction with accompanying drawing, the present invention will be further described;

首先请参阅附图1,本发明的安全微球由能载有纯β射线的玻璃微球1和耐蚀涂层2组成。能载有纯β射线的玻璃微球1可以是含Y2O3、SiO2、Al2O3的Y-89玻璃微球,也可以是含P2O5、Al2O3、MgO的P-31玻璃微球。Please refer to accompanying drawing 1 at first, safety microsphere of the present invention is made up of glass microsphere 1 and corrosion-resistant coating 2 that can be loaded with pure beta ray. The glass microspheres 1 that can carry pure β rays can be Y-89 glass microspheres containing Y 2 O 3 , SiO 2 , Al 2 O 3 , or they can be those containing P 2 O 5 , Al 2 O 3 , MgO P-31 glass microspheres.

接着请参阅附图2,本发明的制备安全微球的方法如下:首先将玻璃微球1放入容器中,喷洒入0.3~0.5克表面活性剂聚乙二醇或硅烷偶联剂,搅拌,使之湿润完成预处理3。然后将上述玻璃微球1浸泡在由正硅酸乙酯50-100%、硝酸铝0-30%、钛酸丁酯0-20%、硝酸锆0-30%组成的溶胶溶液的容器内,置于磁力搅拌器上,搅拌,进行玻璃微球表面包敷凝胶处理4。接下去进行固液分离5。再下去将玻璃微球1和40-60℃热风同方向进入旋风干燥器进行干燥6,去除部分有机溶剂后使湿凝胶变为干凝胶。室温下陈化20-30天,使凝胶稳定7。最后在马弗炉内300-600℃下加热蒸发热处理8,使其玻璃化,形成SiO2、或/和Al2O3、或/和TiO2、或/和ZrO2耐蚀涂层2的本发明的安全微球。Then please refer to accompanying drawing 2, the method for preparing safety microsphere of the present invention is as follows: first put glass microsphere 1 into the container, spray into 0.3~0.5 gram surfactant polyethylene glycol or silane coupling agent, stir, Make it moist to complete pretreatment 3. Then soak the above-mentioned glass microspheres 1 in a container of a sol solution composed of 50-100% tetraethyl orthosilicate, 0-30% aluminum nitrate, 0-20% butyl titanate, and 0-30% zirconium nitrate, Place on a magnetic stirrer, stir, and perform gel coating treatment on the surface of glass microspheres 4. Next, solid-liquid separation 5 is carried out. Going down, the glass microspheres 1 and the 40-60°C hot air enter the cyclone dryer in the same direction for drying 6, and after removing part of the organic solvent, the wet gel becomes a dry gel. Aging at room temperature for 20-30 days stabilizes the gel 7. Finally, heating and evaporating heat treatment 8 at 300-600°C in a muffle furnace to make it vitrified to form SiO 2 , or/and Al 2 O 3 , or/and TiO 2 , or/and ZrO 2 corrosion-resistant coating 2 Safety microspheres of the present invention.

实施例1:Example 1:

将100克含有Y2O3、SiO2、Al2O3的Y-89玻璃微球1置于容器内,加入0.4克的硅烷偶联剂表面活性剂,搅拌完成预处理3,然后浸泡在含100%正硅酸乙酯溶液溶胶中,放在磁力搅拌台上,搅拌进行凝胶化包敷处理4,然后固液分离5,将涂覆好的玻璃微球取出,在旋风干燥器进口与同方向进入的干燥的热风一起进行旋风干燥6,去除部分有机溶剂后,室温下陈化25天时间,使其聚合稳定7,最后在马弗炉内500-600℃下加热蒸发热处理8,使其玻璃化,即制得本发明的表面有SiO2涂层的含钇安全微球。这种安全玻璃微球的直径在20~60μm范围内。涂有SiO2涂层的这种玻璃微球在生理模拟液中30天钇的溶出率为9.0×10-7g/g,而原玻璃微球的溶出率为3.6×10-5g/g,降低了2个数量级。本发明的玻璃微球经中子激活能载有纯β射线的核素Y-90,具有对人体所有的癌细胞都产生很强的杀死杀伤能力。Put 100 grams of Y-89 glass microspheres 1 containing Y 2 O 3 , SiO 2 , and Al 2 O 3 in a container, add 0.4 grams of silane coupling agent surfactant, stir to complete pretreatment 3, and then soak in Containing 100% tetraethyl orthosilicate solution sol, put it on a magnetic stirring table, stir for gelation and coating treatment 4, then separate solid and liquid 5, take out the coated glass microspheres, and place them in the cyclone dryer inlet Cyclone drying 6 together with the dry hot air entering in the same direction, after removing part of the organic solvent, aging at room temperature for 25 days to stabilize the polymerization 7, and finally heating and evaporating heat treatment at 500-600°C in a muffle furnace 8, Make it vitrified, promptly make the surface of the present invention have SiO The yttrium -containing safety microsphere of coating. The diameter of the safety glass microspheres is in the range of 20-60 μm. The yttrium dissolution rate of this glass microsphere coated with SiO 2 coating was 9.0×10 -7 g/g in the physiological simulated solution for 30 days, while the dissolution rate of the original glass microsphere was 3.6×10 -5 g/g , which is reduced by 2 orders of magnitude. The glass microsphere of the present invention can carry nuclide Y-90 of pure beta ray through neutron activation, and has a strong ability to kill all cancer cells in the human body.

实施例2:Example 2:

将100克含有P2O5、Al2O3、MgO的P-31玻璃微球1在0.5克聚乙二醇,搅拌,使之湿润,完成预处理3。然后将上述玻璃微球1浸泡在能形成耐蚀涂层2的由含正硅酸乙酯80-90%、硝酸铝10-20%组成的溶胶溶液中搅拌,进行凝胶化包敷处理4,经上述处理过的玻璃微球凝胶物质,进行固液分离5,将涂覆溶胶的玻璃微球1取出,在旋风干燥器进口与同方向进入的干燥的40-60℃热风一起进行旋风干燥6,去除部分有机溶剂后室温下陈化30天时间,使其聚合稳定7,最后在马弗炉内400-500℃下加热蒸发热处理8,使其玻璃化,得到表面有SiO2和Al2O3涂层的含磷安全微球。这种安全微球的直径在15~55μm范围内。涂有SiO2和Al2O3涂层的这种玻璃微球在生理模拟液中30天磷的溶出率为2.2×10-5g/g,原玻璃微球的溶出率为7.9×10-3g/g,降低了1~2个数量级。100 grams of P-31 glass microspheres 1 containing P 2 O 5 , Al 2 O 3 , and MgO were mixed with 0.5 grams of polyethylene glycol, stirred to make it wet, and pretreatment 3 was completed. Then soak the above-mentioned glass microspheres 1 in a sol solution composed of 80-90% tetraethyl orthosilicate and 10-20% aluminum nitrate capable of forming a corrosion-resistant coating 2, and stir to perform gel coating treatment 4 , the above-mentioned treated glass microsphere gel substance is subjected to solid-liquid separation 5, the glass microsphere 1 coated with sol is taken out, and the cyclone is carried out at the entrance of the cyclone dryer together with the dry hot air at 40-60°C entering in the same direction Drying 6, removing part of the organic solvent and aging at room temperature for 30 days to stabilize the polymerization 7, and finally heating and evaporating heat treatment 8 in a muffle furnace at 400-500 ° C to make it vitrified, and obtain SiO 2 and Al on the surface 2 O 3 coated phosphorus-containing safety microspheres. The diameter of the safety microsphere is in the range of 15-55 μm. The glass microspheres coated with SiO 2 and Al 2 O 3 had a phosphorus dissolution rate of 2.2×10 -5 g/g in a physiological simulated solution for 30 days, and the dissolution rate of the original glass microspheres was 7.9×10 - 3 g/g, reduced by 1 to 2 orders of magnitude.

实施例3:Example 3:

将100克含有P2O5、Al2O3、MgO的P-31玻璃微球1在0.5克聚乙二醇,搅拌,使之湿润,完成预处理3。然后将上述玻璃微球1浸泡在能形成耐蚀涂层2的由含正硅酸乙酯80-95%、钛酸丁酯5-20%组成的溶胶溶液中搅拌,进行凝胶化包敷处理4,经上述处理过的玻璃微球凝胶物质,进行固液分离5,将涂覆溶胶的玻璃微球1取出,在旋风干燥器进口与同方向进入的干燥的40-60℃热风一起进行旋风干燥6,去除部分有机溶剂后室温下陈化30天时间,使其聚合稳定7,最后在马弗炉内400-500℃下加热蒸发热处理8,使其玻璃化,得到表面有SiO2和TiO2涂层的含磷安全微球。这种安全微球的直径在15~55μm范围内。涂有SiO2和TiO2涂层的这种玻璃微球在生理模拟液中30天磷的溶出率为5.3×10-5g/g,原玻璃微球的溶出率为7.9×10-3g/g,降低了1~2个数量级。100 grams of P-31 glass microspheres 1 containing P 2 O 5 , Al 2 O 3 , and MgO were mixed with 0.5 grams of polyethylene glycol, stirred to make it wet, and pretreatment 3 was completed. Then soak the above-mentioned glass microspheres 1 in a sol solution composed of 80-95% tetraethyl orthosilicate and 5-20% butyl titanate that can form a corrosion-resistant coating 2 and stir to carry out gel coating Treatment 4, the glass microsphere gel material treated above is subjected to solid-liquid separation 5, the glass microsphere 1 coated with sol is taken out, and the dry hot air at 40-60°C entering in the same direction is placed at the entrance of the cyclone dryer Carry out cyclone drying 6, remove part of the organic solvent, and age at room temperature for 30 days to stabilize the polymerization 7, and finally heat and evaporate heat treatment 8 in a muffle furnace at 400-500°C to vitrify it, and obtain SiO 2 on the surface and TiO2- coated phosphorus-containing safety microspheres. The diameter of the safety microsphere is in the range of 15-55 μm. The dissolution rate of phosphorus in the glass microspheres coated with SiO 2 and TiO 2 in the physiological simulation solution for 30 days is 5.3×10 -5 g/g, and the dissolution rate of the original glass microspheres is 7.9×10 -3 g /g, decreased by 1 to 2 orders of magnitude.

实施例4:Example 4:

将100克含有P2O5、Al2O3、MgO的P-31玻璃微球1在0.5克聚乙二醇,搅拌,使之湿润,完成预处理3。然后将上述玻璃微球1浸泡在能形成耐蚀涂层2的由含正硅酸乙酯80-95%、硝酸锆5-20%组成的溶胶溶液中搅拌,进行凝胶化包敷处理4,经上述处理过的玻璃微球凝胶物质,进行固液分离5,将涂覆溶胶的玻璃微球1取出,在旋风干燥器进口与同方向进入的干燥的40-60℃热风一起进行旋风干燥6,去除部分有机溶剂后室温下陈化30天时间,使其聚合稳定7,最后在马弗炉内400-500℃下加热蒸发热处理8,使其玻璃化,得到表面有SiO2和ZrO2涂层的含磷安全微球。这种安全微球的直径在15~55μm范围内。涂有SiO2和ZrO2涂层的这种玻璃微球在生理模拟液中30天磷的溶出率为6.4×10-6g/g,原玻璃微球的溶出率为7.9×10-3g/g,降低了3个数量级。100 grams of P-31 glass microspheres 1 containing P 2 O 5 , Al 2 O 3 , and MgO were mixed with 0.5 grams of polyethylene glycol, stirred to make it wet, and pretreatment 3 was completed. Then soak the above-mentioned glass microspheres 1 in a sol solution composed of 80-95% tetraethyl orthosilicate and 5-20% zirconium nitrate capable of forming a corrosion-resistant coating 2, and stir to perform gel coating treatment 4 , the above-mentioned treated glass microsphere gel substance is subjected to solid-liquid separation 5, the glass microsphere 1 coated with sol is taken out, and the cyclone is carried out at the entrance of the cyclone dryer together with the dry hot air at 40-60°C entering in the same direction Drying 6, removing part of the organic solvent, aging at room temperature for 30 days to stabilize the polymerization 7, and finally heating and evaporating heat treatment 8 in a muffle furnace at 400-500 ° C to make it vitrified, and obtain SiO 2 and ZrO on the surface 2- coated phosphorus-containing safety microspheres. The diameter of the safety microsphere is in the range of 15-55 μm. The dissolution rate of phosphorus in the glass microspheres coated with SiO 2 and ZrO 2 is 6.4×10 -6 g/g in the physiological simulated liquid for 30 days, and the dissolution rate of the original glass microspheres is 7.9×10 -3 g /g, reduced by 3 orders of magnitude.

Claims (4)

1, a kind of safe microball of pure beta ray corrying is characterized in that: be composited by the glass microsphere (1) of pure beta ray corrying and the anti-corrosion coating (2) that is coated on its outer surface thereof.
2, safe microball according to claim 1 is characterized in that: described anti-corrosion coating (2) can be SiO 2, or/and Al 2O 3, or/and TiO 2, or/and ZrO 2
3, safe microball according to claim 1 is characterized in that: the glass microsphere of described pure beta ray corrying (1) can be to contain Y 2O 3, SiO 2, Al 2O 3The Y-89 glass microsphere, also can be to contain P 2O 5, Al 2O 3, MgO the P-31 glass microsphere.
4, a kind of preparation method of safe microball of pure beta ray corrying, it is characterized in that: at first in glass microsphere (1), add surfactant and stir, carry out pretreatment (3), then it is immersed in can form anti-corrosion coating (2) by tetraethoxysilance 50-100%, aluminum nitrate 0-31%, carbonic acid fourth fat 0-20%, stir in the sol solution that zirconium nitrate 0-30% forms, finish the coated processing of gelation (4), the subsequent filtration (5), subsequent again carrying out after cyclone drying (6) removes organic solvent, under the room temperature ageing 20-30 days (7), 300-600 ℃ of following heating evaporation heat treatment (8) in Muffle furnace at last, make its vitrification, promptly make the safe microball of surface-coated anti-corrosion coating of the present invention (2).
CNB001257412A 2000-10-20 2000-10-20 Pure beta ray corrying safe microball and its preparation Expired - Fee Related CN1141146C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB001257412A CN1141146C (en) 2000-10-20 2000-10-20 Pure beta ray corrying safe microball and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001257412A CN1141146C (en) 2000-10-20 2000-10-20 Pure beta ray corrying safe microball and its preparation

Publications (2)

Publication Number Publication Date
CN1288755A true CN1288755A (en) 2001-03-28
CN1141146C CN1141146C (en) 2004-03-10

Family

ID=4591525

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB001257412A Expired - Fee Related CN1141146C (en) 2000-10-20 2000-10-20 Pure beta ray corrying safe microball and its preparation

Country Status (1)

Country Link
CN (1) CN1141146C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798580B (en) * 2003-04-04 2010-10-13 生物领域医疗公司 Microspheres comprising therapeutic and diagnostic radioactive isotopes
CN110227170A (en) * 2018-03-05 2019-09-13 白金科技股份有限公司 Radiate microballoon and preparation method thereof
CN111202871A (en) * 2018-11-21 2020-05-29 白金科技股份有限公司 Radioactive microsphere and radioactive filler composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798580B (en) * 2003-04-04 2010-10-13 生物领域医疗公司 Microspheres comprising therapeutic and diagnostic radioactive isotopes
CN110227170A (en) * 2018-03-05 2019-09-13 白金科技股份有限公司 Radiate microballoon and preparation method thereof
CN111202871A (en) * 2018-11-21 2020-05-29 白金科技股份有限公司 Radioactive microsphere and radioactive filler composition

Also Published As

Publication number Publication date
CN1141146C (en) 2004-03-10

Similar Documents

Publication Publication Date Title
US6998105B2 (en) Low density radionuclide-containing particulate material
Chao et al. Rhenium‐188 Labeled Tungsten Disulfide Nanoflakes for Self‐Sensitized, Near‐Infrared Enhanced Radioisotope Therapy
US10940219B2 (en) Radioactive microspheres made of nanoporous glass for radiation therapy
JP2004511576A (en) Polymer-based radionuclide-containing particulate material
TWI675669B (en) Radiative microsphere and preparation method thereof
WO2018028642A1 (en) Medical iodine-131 carbon microsphere and method for fabrication thereof
WO2002034299A1 (en) Inorganic low density radionuclide coated particles
CN1141146C (en) Pure beta ray corrying safe microball and its preparation
Day Glasses for radiotherapy
US7316644B2 (en) Method for preparing particles of radioactive powder containing Cesium-131 for use in brachytherapy sources
JP6901498B2 (en) Isotope preparation method
Atroshchenko et al. Glassy microspheres and their applications in nuclear medicine
Zhou et al. Clinically translatable phosphonated silica microspheres for selective internal radiation therapy of hepatocellular carcinoma
US3719750A (en) Radioactive preparation absorbable in organism and method of obtaining same
US20230050728A1 (en) Method of manufacturing silica microspheres
CN118647414A (en) Radiotherapy gel and preparation method thereof
RU2794457C1 (en) Method for errlich adenocarcinoma treatment
KR20240140920A (en) Radiotherapy gel and method of making same
US20230263913A1 (en) Radiotherapy gel and method of preparing the same
CN115869658B (en) Separation system for preparing Ra-223, separation method, application and preparation method thereof
US20240335573A1 (en) Radionuclide microspheres and preparation method therefor and application thereof
CN117695431A (en) Embolic microsphere loaded with radiotherapy nuclide and preparation method thereof
CN117603460A (en) A matrix resin and 90Y resin
CN116715805A (en) A multifunctional gel microsphere rich in bisphosphonic acid groups and its preparation method and application
Man Development of Radiopharmaceutical DW-166HC for Anticancer drug

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
DD01 Delivery of document by public notice

Addressee: Tongji University

Document name: Notification to Pay the Fees

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040310

Termination date: 20141020

EXPY Termination of patent right or utility model